This kit is for qualitative testing of 2019 NCOV neutralization
Antibodies in human serum, plasma and whole blood samples
The 2019 NCOV is the new NCOV. The main clinical symptoms of viral pneumonia are fever, fatigue and dry cough. Some patients complain of stuffy nose, runny nose, sore throat, and diarrhea. Dyspnea or hypoxemia develops after 1 week in severely ill patients, and acute respiratory distress syndrome, infectious shock, metabolic acidosis, and coagulation disorders develop rapidly in severely ill patients.
2019 NCoV contains several structural proteins including spinosaurus, envelope, envelope
(m) and nuclear cosid (n). Of these, the spy protein contains a receptor binding domain (RBD) that is involved in the identification of angiotensin converting enzyme 2 (ACE 2) on the cell surface receptor. It was revealed that the rbd peak of ncov in 2019 strongly interacts with the human aceh2 receptor, causing intracellular receptor in the host and viral replication in the lung.
NCoV infection or vaccination in 2019 provokes an immune response and produces antibodies in the blood. Virus infection can be prevented by secreting an antibody. They are present in the human circulation months to years after infection and rapidly bind to pathogens to prevent viral replication. These antibodies are called neutralizing antibodies. Neutralizing antibody tests determine whether a person is capable of resisting a viral infection.
The kit consists of a test card and sample buffer.
Test card: Consists of aluminum foil packaging, desiccant, test sheet, plastic card. The test paper consists of a water-absorbent paper, a cellulose nitrate film, a test piece pad, an adhesive pad, and a rubber plate. The T line (test line) of the cellulose nitrate membrane is covered with an adhesive pad containing the ACE 2 protein, C line (QC line), AB line, R line (reference line), reference AB and NCOV AB marks.
Sample buffer: Phosphate, sodium nitride, etc.
Keep at 2 ° C~30 ° C and set the validity period to 12 months.
The opening period of the aluminum foil pack is 1 hour.
Lot number: Look at the label.
Deadline: See detail label
1. Collect serum, plasma or whole blood samples.
2. Sediments and suspended solids in the sample affect the experimental results and must be removed by centrifugation.
Anticoagulant therapy Heparin, EDTA, sodium citrate are not important.
3. Blood collection is performed by a professional medical staff. Serum / plasma tests are recommended. The patient's entire blood sample can also be used for rapid testing in emergencies and special cases.
The storage time of serum and plasma samples at room temperature should not exceed 8 hours. They are there
It can be stored at 2-8 degrees Celsius, 5 days Celsius, and 6 months Celsius, but repeated freeze-thaw cycles should be avoided. Whole blood samples should not be frozen and should be stored at 2 ° C-8 ° C for at least 48 hours.
Please read the instructions carefully before testing. Bring all reagents to room temperature.
1. Remove the test card from the packaging kit within an hour.
2. Add l sample (serum, plasma or whole blood) to the load hole, add 2 drops (about 60 drops) to the μ test card, start buffering the μ sample, and start time counting.
3. It reacts at room temperature for 10 to 15 minutes and gives a result, but after 20 minutes, no result is obtained.
Test card result judgment sheet
1. Invalid result: Quality control line (c) is invalid and needs to be retested.
2. Negative result: Red stripes appear above or above the detection line (T line), baseline (R line), quality control line (C line) and baseline (R line).
3. Positive result: The red band on the test line (t), or the following red band on the test line (t), instead of the reference line (r), quality control line (c) and reference line (r).
1. The kit can be used not only for qualitative tests but also for in-vitro assisted diagnosis.
2. Put an appropriate amount of sample in advance and inspect. Results may be inaccurate if there are too many or too small samples.
3. Hemolysis, blood fats, jaundice, and contaminated samples should be avoided as they can affect test results.
4. It should not be the sole basis for clinical trials and treatment. The final diagnosis of this disease should be made by comprehensively assessing the results of all clinical and experimental studies.
1. Analysis of specificity
1.1 Cross reaction: evaluate the interference of the following type of antibody to the reagent and show no cross reaction.
SN | Item | Cross reaction | SN | Item | Cross reaction |
1 | Endemic human coronavirus OC43 | No | 10 | Enterovirus | No |
2 | Endemic human coronavirus HKUI | No | 11 | EB virus | No |
3 | Endemic human coronavirus NL63 | No | 12 | Measles virus | No |
4 | Endemic human coronavirus 229E | No | 13 | Human cytomegalovirus | No |
5 | Influenza A virus | No | 14 | Rotavirus | No |
6 | Influenza B virus | No | 15 | Norovirus | No |
7 | Respiratory syncytial virus | No | 16 | Mumps virus | No |
8 | Adenovirus | No | 17 | Varicella-zoster virus | No |
9 | Rhinovirus | No | 18 | Mycoplasma pneumoniae | No |
1.2 Interfering substances: In the 2019 NCoV and AB test plans, the following concentrations will be added to the sample to assess potential interference. As a result, it was found that each interfering substance did not interfere with the detection result of the reagent.
Interfering substances | Concentration | Interfering substances | Concentration |
Bilirubin | ≤50mg/dL | Triglycerides | ≤15mmol/mL |
Hemoglobin | ≤5g/L | Cholesterol L | ≤500mg/d |
Rheumatoid factor | ≤500IU/mL | Human total IgG | ≤14mg/mL |
Ribavirin | 0.4mg/mL | Fluticasone | 0.5mg/mL |
Oxymetazoline | 10mg/mL | Dexamethasone | 5 mg/mL |
Histamine hydrochloride | 10mg/mL | Triamcinolone acetonide | 5mg /mL |
Tobramycin | 1mg/mL | Levofloxacin | 0.2 mg/mL |
Oseltamivir | 1mg/mL | Azithromycin | 0.1 mg/mL |
Zanamivir | 1mg/mL | Ceftriaxone | 0.4 mg/mL |
Arbidol | 0.5mg/mL | Meropenem | 0.2 mg/mL |
2. Clinical study: 120 positive samples and 300 negative samples are selected using a commercially available 2020 ncov igg antibody detection reagent (colloidal gold method) as a control reagent. The results can be summarized as follows.
2019-nCoV IgG Ab detection reagent (colloidal goldmethod) |
Sum | |||
Positive | Negative | |||
| Positive | 115 | 5 | 120 |
Negtive | 5 | 295 | 300 | |
Sum | 120 | 300 | 420 | |
Sensitivity | 95.83%, (95%CI: 90.62%~98.21%) | |||
Specificity | 98.33%, (95%CI: 96.16%~99.29%) |
1. This product is used only for in vitro diagnosis.
2. This product is a disposable product and cannot be collected.
3. Strictly follow the reagent instructions before surgery to perform the experiment.
4. Avoid experiments in harsh environmental conditions (84 disinfectants, sodium hypochlorite, environments containing corrosive gas and high concentrations of dust, such as acids, alkalis, acetaldehyde). Disinfect after the experiment.
5. Samples and reagents used are considered potential contagious substances and are treated according to local regulations.
6. Reagents should be used within the validity period of the outsourced label. The test card must be removed from the aluminum foil bag and used as soon as possible to prevent moisture.
| Do not re-use |
| Store at 2℃~30℃ |
| Consult instructions for use | | In vitro diagnostic medical device |
| Batch code | | Use-by date |
![]() | Keep dry | | Keep away from sunlight |
| Authorized representative in the European Community | | Manufacturer |
ZHONGXIU SCIENCE AND TECHNOLOGY CO.,LTD
Dingluan industrial zone ,Changyuan City,453400,P.R.CHINA
Tel:+86-371-55016575
Email:zosbio@zosbio.com
Web:www.zosbio.com
SUNGO Europe B.V.
Olympisch Stadion 24, 1076DE Amsterdam, Netherlands